SHAREHOLDER ALERT: Weiss Law Reminds APEN, HZN, CBIO, and AJRD Shareholders About Its Ongoing Investigations
NEW YORK, Jan. 18, 2023 /PRNewswire/ --
If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
[email protected]
Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Apollo Endosurgery, Inc. (NASDAQ: APEN), in connection with the proposed acquisition of APEN by Boston Scientific Corporation. Under the terms of the merger agreement, APEN shareholders will receive $10.00 in cash for each share of APEN common stock owned. If you own APEN shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/apen
Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Horizon Global Corporation (NYSE: HZN) in connection with the proposed acquisition of HZN by First Brands Group, LLC, via tender offer. Under the tender offer, HZN shareholders will receive $1.75 in cash for each share of HZN common stock owned. If you own HZN shares and wish to discuss this investigation or your rights, please call at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/hzn
Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Catalyst Biosciences, Inc. (NASDAQ: CBIO), in connection with the proposed purchase of GNI Group Ltd.'s ("GNI") proprietary new chemical entity F351 ("F351"). This purchase will transfer the global rights to F351 (excluding Mainland China) to CBIO in consideration of 6,266,521 shares of common stock and 12,340 shares of a new series of preferred stock ("Series X") with economic rights equivalent to CBIO common stock to be paid for GNI's 65.18% interest of Beijing Continent ("Continent"), a China based commercial-stage pharmaceutical company marketing pirfenidone and having the rights to F351 in China. If you own CBIO shares and wish to discuss this investigation or your rights, please call at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/cbio
Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aerojet Rocketdyne Holdings, Inc. (NYSE: AJRD), in connection with the proposed acquisition of AJRD by L3Harris Technologies, Inc. Under the terms of the merger agreement, AJRD shareholders will receive $58.00 in cash for each share of AJRD common stock owned. If you own AJRD shares and wish to discuss this investigation or your rights, please call at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/ajrd
SOURCE Weiss Law
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article